The revisions are based on results from a clinical trial of over 4900 patients which showed that Pegintron and weight-based Rebetol dosing resulted in a significantly higher sustained virologic response (SVR) compared to Pegintron combined with a flat dosing regimen of Rebetol. The study also reported low relapse rates consistent with other Pegintron studies.